Welcome to our dedicated page for Palatin Tech news (Ticker: PTN), a resource for investors and traders seeking the latest updates and insights on Palatin Tech stock.
Palatin Technologies, Inc. (PTN) generates a steady flow of news as a biopharmaceutical company centered on melanocortin receptor–based therapeutics. News coverage for PTN often highlights updates on its obesity, ocular, and retinal programs, as well as financing events and stock listing developments. Investors and followers can use this page to review how Palatin’s scientific, clinical, and corporate milestones evolve over time.
Recent press releases have focused on obesity program progress, including preclinical and clinical data for the oral MC4R agonist PL7737 and next-generation peptide MC4R agonists. Palatin has reported robust weight loss and favorable safety in preclinical models, Phase 2 data on co-administration of an MC4R agonist with tirzepatide in obese patients, and regulatory designations such as Orphan Drug status for PL7737 in LEPR deficiency–related obesity. These updates provide insight into the company’s efforts to develop mechanism-based obesity therapies.
Palatin news also covers its ocular and retinal pipeline. Releases describe Phase 3 MELODY-1 data for PL9643 in dry eye disease, including responder analyses showing complete symptom resolution across multiple endpoints, and preclinical findings for PL9654 and PL9655 in diabetic retinopathy that demonstrate inflammation resolution, vascular stabilization, and neuroprotection. Announcements related to the company’s collaboration with Boehringer Ingelheim for retinal diseases further illustrate how Palatin seeks to advance its melanocortin platform through partnerships.
On the corporate side, PTN news items detail public offerings, warrant structures, and exchange listing status, including NYSE American delisting proceedings, trading on OTC markets, a 1-for-50 reverse stock split, and the subsequent resumption of trading on NYSE American. For readers tracking PTN, this news feed brings together scientific presentations, clinical trial readouts, collaboration agreements, and capital markets activity in one place, making it easier to follow Palatin’s development trajectory and key disclosures.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.